Market Overview:
The global sympathomimetic agents market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of cardiac arrest and anaphylaxis, and rising demand for epinephrine auto-injectors. However, the high cost of treatment is a major restraint on the growth of this market. Based on type, the global sympatomimetic agents market is segmented into dobutamine, dopamine, ephedrine, epinephrine, isoproterenol, mephentermine metaraminol methoxamine norepinephrine phenylephrine. Dopamine held the largest share in 2017 owing to its widespread use in various applications such as cardiac arrest and sepsis shock. Epinephrine held second largest share in 2017 due to its high demand for treating anaphylaxis globally. Based on application,the global sympatomimetic agents market is segmented into anaphylaxis,,cardiac arrest,,and others,. Anaphylaxis accounted for majority share in 2017 due to increasing prevalence of allergic reactions across globe .
Product Definition:
A sympathomimetic agent is a drug that mimics the effects of the sympathetic nervous system. This system is responsible for controlling many automatic functions of the body, such as heart rate, blood pressure, and respiration. Sympathomimetic agents are used to treat a variety of conditions, including asthma, allergies, and cardiovascular disorders. They are also used as stimulants to treat narcolepsy and other sleep disorders.
Dobutamine:
Dobutamine is a non-competitive, non-narcotic, pure alpha agonist. It was first synthesized in 1960 and has been used as an off label drug by the medical profession ever since. In recent years it has gained significant attention due to its use as a sports performance enhancing drug by athletes and bodybuilders. However, it can also be used to treat patients with pulmonary hypertension who are suffering from chronic obstructive pulmonary disease (COPD).
Dopamine:
Dopamine is a chemical messenger that facilitates the transmission of signals from one cell to another in the body. Dopamine plays an important role in controlling movement, emotions, and sensations. It is also used as a drug to treat Parkinson's disease which is caused by abnormal movements of the body parts such as tremors, stiffness and walking problems.
Application Insights:
Anaphylaxis was the leading application segment in 2017 and accounted for over 25% of total market share. Anaphylaxis is a severe allergic reaction to a particular allergen that causes symptoms such as shortness of breath, wheezing, skin rashes with raised bumps along with itching and burning sensation. The incidence rate of anaphylaxis is increasing at a rapid pace globally due to rising awareness about food allergies among population especially in developed countries like U.S., Canada, U.K., Germany and France where prevalence rate for peanut allergy is around 2%.
Regional Analysis:
Europe dominated the global symtphemic agents market in 2017. The presence of well-established healthcare facilities and favorable reimbursement policies are some of the major factors contributing to its growth. In addition, increasing prevalence of cardiac disorders and anaphylaxis due to food allergies is expected to drive regional demand over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income, improving healthcare infrastructure, growing awareness about early diagnosis & treatment options for various diseases coupled with rising consumer preference for branded drugs among local players in countries such as China & India. This has led pharmaceutical companies focus on investing in this region which will eventually boost product sales over next eight years.
Growth Factors:
- Increasing prevalence of lifestyle diseases such as obesity, hypertension, and diabetes which can be treated with sympathomimetic agents.
- Growing demand for drugs to treat cardiac conditions such as arrhythmias and congestive heart failure.
- Rising geriatric population who are more susceptible to the effects of sympathomimetic agents.
- increasing use of sympathomimetics in emergency medicine for the treatment of conditions such as anaphylaxis, asthma, and shock.
Scope Of The Report
Report Attributes
Report Details
Report Title
Sympathomimetic Agents Market Research Report
By Type
Dobutamine, Dopamine, Ephedrine, Epinephrine, Isoproterenol, Mephentermine, Metaraminol, Methoxamine, Norepinephrine, Phenylephrine
By Application
Anaphylaxis, Cardiac Arrest, Others
By Companies
Pfizer, Sanofi, Novartis, Sterimax, Bedford Pharmaceuticals, Teva, Amneal Biosciences, Baxter Laboratories, Hikma Pharmaceuticals, Amphastar Pharmaceuticals, Marathon Pharmaceuticals, Bausch Health Companies, Sterling-Winthrop, Cipla USA, Nexus Pharmaceuticals, Mylan, Impax, ALK Abello, Lincoln Medical, Amphastar, Emerade, Grand Pharma, Harvest Pharmaceuticals, Merit Pharmaceutical, Tianjin Jinyao Group
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
223
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Sympathomimetic Agents Market Report Segments:
The global Sympathomimetic Agents market is segmented on the basis of:
Types
Dobutamine, Dopamine, Ephedrine, Epinephrine, Isoproterenol, Mephentermine, Metaraminol, Methoxamine, Norepinephrine, Phenylephrine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anaphylaxis, Cardiac Arrest, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Sanofi
- Novartis
- Sterimax
- Bedford Pharmaceuticals
- Teva
- Amneal Biosciences
- Baxter Laboratories
- Hikma Pharmaceuticals
- Amphastar Pharmaceuticals
- Marathon Pharmaceuticals
- Bausch Health Companies
- Sterling-Winthrop
- Cipla USA
- Nexus Pharmaceuticals
- Mylan
- Impax
- ALK Abello
- Lincoln Medical
- Amphastar
- Emerade
- Grand Pharma
- Harvest Pharmaceuticals
- Merit Pharmaceutical
- Tianjin Jinyao Group
Highlights of The Sympathomimetic Agents Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Dobutamine
- Dopamine
- Ephedrine
- Epinephrine
- Isoproterenol
- Mephentermine
- Metaraminol
- Methoxamine
- Norepinephrine
- Phenylephrine
- By Application:
- Anaphylaxis
- Cardiac Arrest
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sympathomimetic Agents Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Some of the key players operating in the sympathomimetic agents market are Pfizer, Sanofi, Novartis, Sterimax, Bedford Pharmaceuticals, Teva, Amneal Biosciences, Baxter Laboratories, Hikma Pharmaceuticals, Amphastar Pharmaceuticals, Marathon Pharmaceuticals, Bausch Health Companies, Sterling-Winthrop, Cipla USA, Nexus Pharmaceuticals, Mylan, Impax, ALK Abello, Lincoln Medical, Amphastar, Emerade, Grand Pharma, Harvest Pharmaceuticals, Merit Pharmaceutical, Tianjin Jinyao Group.
The sympathomimetic agents market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Sympathomimetic Agents Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Sympathomimetic Agents Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Sympathomimetic Agents Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Sympathomimetic Agents Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Sympathomimetic Agents Market Size & Forecast, 2018-2028
4.5.1 Sympathomimetic Agents Market Size and Y-o-Y Growth
4.5.2 Sympathomimetic Agents Market Absolute $ Opportunity
Chapter 5 Global Sympathomimetic Agents Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Sympathomimetic Agents Market Size Forecast by Type
5.2.1 Dobutamine
5.2.2 Dopamine
5.2.3 Ephedrine
5.2.4 Epinephrine
5.2.5 Isoproterenol
5.2.6 Mephentermine
5.2.7 Metaraminol
5.2.8 Methoxamine
5.2.9 Norepinephrine
5.2.10 Phenylephrine
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Sympathomimetic Agents Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Sympathomimetic Agents Market Size Forecast by Applications
6.2.1 Anaphylaxis
6.2.2 Cardiac Arrest
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Sympathomimetic Agents Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Sympathomimetic Agents Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Sympathomimetic Agents Analysis and Forecast
9.1 Introduction
9.2 North America Sympathomimetic Agents Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Sympathomimetic Agents Market Size Forecast by Type
9.6.1 Dobutamine
9.6.2 Dopamine
9.6.3 Ephedrine
9.6.4 Epinephrine
9.6.5 Isoproterenol
9.6.6 Mephentermine
9.6.7 Metaraminol
9.6.8 Methoxamine
9.6.9 Norepinephrine
9.6.10 Phenylephrine
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Sympathomimetic Agents Market Size Forecast by Applications
9.10.1 Anaphylaxis
9.10.2 Cardiac Arrest
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Sympathomimetic Agents Analysis and Forecast
10.1 Introduction
10.2 Europe Sympathomimetic Agents Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Sympathomimetic Agents Market Size Forecast by Type
10.6.1 Dobutamine
10.6.2 Dopamine
10.6.3 Ephedrine
10.6.4 Epinephrine
10.6.5 Isoproterenol
10.6.6 Mephentermine
10.6.7 Metaraminol
10.6.8 Methoxamine
10.6.9 Norepinephrine
10.6.10 Phenylephrine
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Sympathomimetic Agents Market Size Forecast by Applications
10.10.1 Anaphylaxis
10.10.2 Cardiac Arrest
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Sympathomimetic Agents Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Sympathomimetic Agents Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Sympathomimetic Agents Market Size Forecast by Type
11.6.1 Dobutamine
11.6.2 Dopamine
11.6.3 Ephedrine
11.6.4 Epinephrine
11.6.5 Isoproterenol
11.6.6 Mephentermine
11.6.7 Metaraminol
11.6.8 Methoxamine
11.6.9 Norepinephrine
11.6.10 Phenylephrine
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Sympathomimetic Agents Market Size Forecast by Applications
11.10.1 Anaphylaxis
11.10.2 Cardiac Arrest
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Sympathomimetic Agents Analysis and Forecast
12.1 Introduction
12.2 Latin America Sympathomimetic Agents Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Sympathomimetic Agents Market Size Forecast by Type
12.6.1 Dobutamine
12.6.2 Dopamine
12.6.3 Ephedrine
12.6.4 Epinephrine
12.6.5 Isoproterenol
12.6.6 Mephentermine
12.6.7 Metaraminol
12.6.8 Methoxamine
12.6.9 Norepinephrine
12.6.10 Phenylephrine
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Sympathomimetic Agents Market Size Forecast by Applications
12.10.1 Anaphylaxis
12.10.2 Cardiac Arrest
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Sympathomimetic Agents Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Sympathomimetic Agents Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Sympathomimetic Agents Market Size Forecast by Type
13.6.1 Dobutamine
13.6.2 Dopamine
13.6.3 Ephedrine
13.6.4 Epinephrine
13.6.5 Isoproterenol
13.6.6 Mephentermine
13.6.7 Metaraminol
13.6.8 Methoxamine
13.6.9 Norepinephrine
13.6.10 Phenylephrine
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Sympathomimetic Agents Market Size Forecast by Applications
13.10.1 Anaphylaxis
13.10.2 Cardiac Arrest
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Sympathomimetic Agents Market: Competitive Dashboard
14.2 Global Sympathomimetic Agents Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Sanofi
14.3.3 Novartis
14.3.4 Sterimax
14.3.5 Bedford Pharmaceuticals
14.3.6 Teva
14.3.7 Amneal Biosciences
14.3.8 Baxter Laboratories
14.3.9 Hikma Pharmaceuticals
14.3.10 Amphastar Pharmaceuticals
14.3.11 Marathon Pharmaceuticals
14.3.12 Bausch Health Companies
14.3.13 Sterling-Winthrop
14.3.14 Cipla USA
14.3.15 Nexus Pharmaceuticals
14.3.16 Mylan
14.3.17 Impax
14.3.18 ALK Abello
14.3.19 Lincoln Medical
14.3.20 Amphastar
14.3.21 Emerade
14.3.22 Grand Pharma
14.3.23 Harvest Pharmaceuticals
14.3.24 Merit Pharmaceutical
14.3.25 Tianjin Jinyao Group
